Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,445
datasets available to search
ShareScore release 0.9.0
Dataset results
1,445 results for “Irradiation”
UV irradiation remodels the specificity landscape of transcription factors [85438_Proteins]
GEO Series GSE223017. synthetic construct; Homo sapiens; Arabidopsis thaliana. 16 samples. Type: Other.
Next Generation Sequencing Facilitates Quantitative Analysis of wild type and Lmna R527C mutant mice spleen Transcriptomes with or without 4Gy irradiation.
GEO Series GSE190199. Mus musculus. 8 samples. Type: Expression profiling by high throughput sequencing.
Circle-seq of skin samples from SD rats irradiated with different fractional electron beam radiation
GEO Series GSE218553. Rattus norvegicus. 12 samples. Type: Other.
MiRNA microarray for exosome of H1299 cells after irradiation
GEO Series GSE211840. Homo sapiens. 2 samples. Type: Non-coding RNA profiling by array.
Genome-wide maps of deaminated CPDs (dCPDs) following UV-irradiation in cells and deamination as naked DNA in vitro
GEO Series GSE285152. Saccharomyces cerevisiae. 8 samples. Type: Other.
RNA Seq analysis of gene expression in Planaria at 24, 48, 72, and 96 hours after exposure to 6k rad of gamma irradiation.
GEO Series GSE80540. Schmidtea mediterranea. 15 samples. Type: Expression profiling by high throughput sequencing.
Age dependence of hematopoietic progenitor survival and chemokine family gene induction after gamma-irradiation in bone marrow tissue in C3H mice
GEO Series GSE47663. Mus musculus. 18 samples. Type: Expression profiling by array.
DNA methylation analysis by DREAM of UV irradiated melanocytes
GEO Series GSE169695. Mus musculus; Homo sapiens. 16 samples. Type: Methylation profiling by high throughput sequencing.
Biological characteristics of gene expression features in pancreatic cancer cell induced by proton and x-ray irradiation IV
GEO Series GSE107443. Homo sapiens. 8 samples. Type: Expression profiling by array.
RNA sequencing analysis of control, photon- and proton- irradiated salivary gland organoids at 2 and 6 days post irradiation
GEO Series GSE253034. Mus musculus. 48 samples. Type: Expression profiling by high throughput sequencing.
Radiation effects on lung carcinogenesis in neonatal, juvenile, and adult Wistar rats after thoracic X-ray irradiation
GEO Series GSE78869. Rattus norvegicus. 12 samples. Type: Genome variation profiling by genome tiling array.
Expression data after irradiating mMSCs
GEO Series GSE41106. Mus musculus. 18 samples. Type: Expression profiling by array.
The transcriptomic profile of the hippocampal microglia in the irradiated juvenile mouse brain
GEO Series GSE149522. Mus musculus. 48 samples. Type: Expression profiling by high throughput sequencing.
Single cell RNA-seq activated microglia cells after irradiation (IR)
GEO Series GSE149247. Mus musculus. 4 samples. Type: Expression profiling by high throughput sequencing.
Dataset related to article "Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO)"
<p>Abstract</p> <p>INTRODUCTION:</p> <p>The prognosis of glioma is dismal, and almost all patients relapsed. At recurrence time, several treatment options are considered, but to date there is no a standard of care. The Neurooncology Study Group of the Italian Association of Radiation Oncology (AIRO) collected clinical data regarding a large series of recurrent glioma patients who underwent re-irradiation (re-RT) in Italy.</p> <p>METHODS:</p> <p>Data regarding 300 recurrent glioma patients treated from May 2002 to November 2017, were analyzed. All patients underwent re-RT. Surgical resection, followed by re-RT with concomitant and adjuvant chemotherapy was performed. Clinical outcome was evaluated by neurological examination and brain MRI performed, 1 month after radiation therapy and then every 3 months.</p> <p>RESULTS:</p> <p>Re-irradiation was performed at a median interval time (IT) of 16 months from the first RT. Surgical resection before re-RT was performed in 19% of patients, concomitant temozolomide (TMZ) in 16.3%, and maintenance chemotherapy in 29%. Total doses ranged from 9 Gy to 52.5 Gy, with a median biological effective dose of 43 Gy. The median, 1, 2 year OS were 9.7 months, 41% and 17.7%. Low grade glioma histology (p  ≪ 0.01), IT > 12 months (p = 0.001), KPS > 70 (p = 0.004), younger age (p = 0.001), high total doses delivered (p = 0.04), and combined treatment performed (p = 0.0008) were recorded as conditioning survival.</p> <p>CONCLUSION:</p> <p>our data underline re-RT as a safe and feasible treatment with limited rate of toxicity, and a combined ones as a better option for selected patients. The identification of a BED threshold able to obtain a greater benefit on OS, can help in designing future prospective studies.</p>
Dataset related to article "The Potential Role of Intensity-modulated Proton Therapy in the Regional Nodal Irradiation of Breast Cancer: A Treatment Planning Study."
<p>AIMS:</p> <p>To investigate the role of intensity-modulated proton therapy (IMPT) for regional nodal irradiation in patients with breast carcinoma in comparison with volumetric-modulated arc therapy (VMAT).</p> <p>MATERIALS AND METHODS:</p> <p>A cohort of 20 patients (10 in the breast-conserving surgery group and 10 post-mastectomy patients with tissue expander implants) was investigated. Proton plans were also computed using robust optimisation methods. Plan quality was assessed by means of dose-volume histograms and scored with conventional metrics. Estimates of the risk of secondary cancer induction (excess absolute risk, EAR) were carried out, taking into account fractionation, repopulation and repair.</p> <p>RESULTS:</p> <p>Concerning target coverage, the data proved a substantial equivalence of VMAT and IMPT: for example, coverage for the 50 Gy target, expressed in terms of V<sub>98%</sub>, was 47.8 ± 0.4, 47.6 ± 0.4, 47.3 ± 0.8, consistent with the objective of 47.5 Gy, for post-mastectomy patients for the three groups of patients. Also, the conformality of the dose distributions was similar for the two techniques, about 1.1, without statistically significant differences. Organ at risk planning aims were achieved for all structures for both techniques. The mean dose to the ipsilateral lung was 10.8 ± 1.1, 6.2 ± 0.8, 7.2 ± 1.0; for the contralateral lung was 3.2 ± 0.7, 0.3 ± 0.2, 0.4 ± 0.2; for the contralateral breast was: 3.1 ± 0.7, 0.3 ± 0.3 and 0.3 ± 0.3, whereas it was 3.9 ± 0.9, 0.4 ± 0.3 and 0.5 ± 0.5, respectively, for the heart for VMAT, IMPT and robust IMPT plans over the whole group of patients. Robust optimisation affected the near-to-maximum dose values for contralateral lung and breast, the mean dose for the heart and ipsilateral lung, with a deterioration ranging from 20 to 40% of the nominal value of IMPT plans (e.g. from 8.1 ± 6.4 to 11.4 ± 8.8 for the heart compared with 16.2 ± 5.2 for the VMAT plans). The numerical values of EAR per 10 000 patient-years were about one order of magnitude higher for VMAT than for IMPT for contralateral structures: 11.66 ± 2.01, 0.89 ± 0.80, 0.98 ± 0.77 for the contralateral breast and the three groups of plans, respectively; 14.31 ± 2.75, 1.42 ± 0.80, 1.78 ± 0.87 for the contralateral lung; and 34.86 ± 2.64, 18.85 ± 2.15, 20.98 ± 2.35 for the ipsilateral lung.</p> <p>CONCLUSION:</p> <p>IMPT with or without robust optimisation seems to be a potentially promising approach for the radiation treatment of breast cancer when nodal volumes should be irradiated. This was measured in terms of dosimetric advantage and predicted clinical benefit. In fact, the significant reduction in estimated EAR could add further clinical value to the dosimetric sparing of the organs at risk achievable with IMPT.</p>
Dataset related to article: "Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction"
<p>This record contains data related to article: "Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction"</p> <p>Abstract</p> <p><strong>Background: </strong> To investigate the role of intensity modulated proton therapy (IMPT) compared to volumetric modulated arc therapy (VMAT) for advanced supradiaphragmatic Hodgkin's lymphoma (HL) in young female patients by assessing dosimetric features and modelling the risk of treatment related complications and radiation-induced secondary malignancies.</p> <p><strong>Methods: </strong> A group of 20 cases (planned according to the involved-site approach) were retrospectively investigated in a comparative planning study. Intensity modulated proton plans (IMPT) were compared to VMAT RapidArc plans (RA). Estimates of toxicity were derived from normal tissue complication probability (NTCP) calculations with either the Lyman or the Poisson models for a number of endpoints. Estimates of the risk of secondary cancer induction were determined for lungs, breasts, esophagus and thyroid. A simple model-based selection strategy was considered as a feasibility proof for the individualized selection of patients suitable for proton therapy.</p> <p><strong>Results: </strong> IMPT and VMAT plans resulted equivalent in terms of target dose distributions, both were capable to ensure high coverage and homogeneity. In terms of conformality, IMPT resulted ~ 10% better than RA plans. Concerning organs at risk, IMPT data presented a systematic improvement (highly significant) over RA for all organs, particularly in the dose range up to 20Gy. This lead to a composite average reduction of NTCP of 2.90 ± 2.24 and a reduction of 0.26 ± 0.22 in the relative risk of cardiac failures. The excess absolute risk per 10,000 patients-years of secondary cancer induction was reduced, with IMPT, of 9.1 ± 3.2, 7.2 ± 3.7 for breast and lung compared to RA. The gain in EAR for thyroid and esophagus was lower than 1. Depending on the arbitrary thresholds applied, the selection rate for proton treatment would have ranged from 5 to 75%.</p> <p><strong>Conclusion: </strong> In relation to young female patients with advanced supradiaphragmatic HL, IMPT can in general offer improved dose-volume sparing of organs at risk leading to an anticipated lower risk of early or late treatment related toxicities. This would reflect also in significantly lower risk of secondary malignancies induction compared to advanced photon based techniques. Depending on the selection thresholds and with all the limits of a non-validated and very basic model, it can be anticipated that a significant fraction of patients might be suitable for proton treatments if all the risk factors would be accounted for.</p> <p> </p>
Dataset related to article "Hypofractionated Whole Breast Irradiation and Simultaneous Integrated Boost in Large-breasted Patients: Long-term Toxicity and Cosmesis"s
<p>This record contains data related to article "Hypofractionated Whole Breast Irradiation and Simultaneous Integrated Boost in Large-breasted Patients: Long-term Toxicity and Cosmesis"</p> <p>Abstract</p> <p><strong>Introduction: </strong>The purpose of this study was to evaluate the impact of breast size on long-term toxicity and cosmesis in patients with breast cancer treated with hypofractionated simultaneous integrated boost (SIB) using volumetric modulated arc therapy (VMAT).</p> <p><strong>Patients and methods: </strong>Patients with early stage breast cancer were treated with 3-week hypofractionated SIB-VMAT to the whole breast (40.5 Gy) and tumor bed (48 Gy). Two cohorts were identified: small/medium- (< 1000 cm<sup>3</sup>) and large- (> 1000 cm<sup>3</sup>) breasted patients. Acute and late (at 2 and 5 years) skin toxicity and cosmetic data were analyzed. Univariate and multivariate analysis evaluated associations between toxicity and dosimetric/anatomical variables.</p> <p><strong>Results: </strong>From August 2010 to March 2017, a total of 1160 patients were treated; 831 had at least 2 years of follow-up and were analyzed. Treated skin area (TSA) receiving at least 20 Gy > 400 cm<sup>2</sup> and V<sub>105% of Boost</sub> > 5 cm<sup>3</sup> were significant predictors for acute skin toxicity. Multivariate analysis at 2 years was significant for boost volume > 70 cm<sup>3</sup>, TSA > 400 cm<sup>2</sup>, and breast size > 1500 cm<sup>3</sup>. At 5 year analysis (352 patients), none of the analyzed variables was significant. For cosmetic outcome, only the breast size (> 1000 cm<sup>3</sup>) and the boost size > 70 cm<sup>3</sup> at 2 and 5 years, respectively, confirmed significance.</p> <p><strong>Conclusions: </strong>The TSA > 400 cm<sup>2</sup> resulted as a significant predictor of both acute and late skin toxicity at 2 years; however, at 5 years, no breast size or dosimetric parameter suggested indications for increased toxicity. A worse cosmetic outcome was recorded at the 2-year follow up for large breasts, but was not confirmed at the 5-year follow-up. These long-term data suggest that hypofractionated SIB-VMAT is a viable modality also in large-breasted patients.</p>
Dataset related to article "Re-irradiation for recurrent high grade glioma (HGG) patients: Results of a single arm prospective phase 2 study"
<p>This record contains raw data related to article “Re-irradiation for recurrent high grade glioma (HGG) patients: Results of a single arm prospective phase 2 study"</p> <p><strong>Background and purpose: </strong> Standard of care for recurrent high grade glioma (HGG) is missing. Several treatment options have been investigated including re-irradiation (re-RT). Results are promising but provided by retrospective studies. We designed a single arm prospective phase II study aiming to evaluate efficacy, and toxicity of re-irradiation.</p> <p><strong>Materials and methods: </strong> Adults patients with good performance status, HGG diagnosis reclassified according to the new 2021 fifth edition WHO CNS classification, an interval time (IT) from previous RT ≥ 6 months were included. Outcome was evaluated by MRI imaging at 1 month, and every 3 months thereafter. Toxicities were evaluated in terms of radionecrosis occurrence, and neurocognitive status.</p> <p><strong>Results: </strong> Ninety recurrent HGG patients were treated, 11 oligodendroglioma grade 3, 18 astrocytoma grade 3 and 4, and 61 glioblastoma grade 4. The median age was 54 years, and majority had KPS 90-100. The median IT between first-RT and re-RT was 24 months. Re-surgery has been performed in 56.6%, and chemotherapy in 53.3%. The median follow up time was 64 months; median overall survival (OS) time,1,2,3-year OS rates were 17 months (95%CI 14-19), 66.7%±4.9, 32.6%±5.0, and 22.2 ± 4.7. Prognostic factors impacting on survival were age (p = 0.0154), IT between first RT and re-RT (p = 0.0051), glioma grade (p = 0.0090), and IDH status (p = 0.0001). Radionecrosis grade 2-3 occurred in 9 (10%) patients; neurocognitive functions remained stable until disease progression.</p> <p><strong>Conclusion: </strong> Re-RT proved to be a safe and feasible treatment option with low toxicity. Younger patients with grade 3 IDH mutated gliomas, and a longer IT had the better outcome.</p>
Dataset related to article "Automatic Planning of the Lower-Extremities for Total Marrow Irradiation Using Volumetric Modulated Arc Therapy"
<p>This record contains raw data related to article "Automatic Planning of the Lower-Extremities for Total Marrow Irradiation Using Volumetric Modulated Arc Therapy"</p> <p><strong>Abstract</strong></p> <p><strong>Purpose</strong>: Total marrow (and lymphoid) irradiation (TMI-TMLI) is limited by the couch travel range of modern linacs, which forces to split the treatment delivery into two plans with opposite orientations: a head-first supine upper-body plan, and a feet-first supine lower-extremities plan. A specific field junction is thus needed to obtain adequate target coverage in the overlap region of the two plans. In this study, an automatic procedure was developed for field junction creation and lower-extremities plan optimization.</p> <p><strong>Methods</strong>: Ten patients treated with TMI-TMLI at our institution were selected retrospectively. The planning of the lower-extremities was performed automatically. Target volume parameters (CTV_J-V<sub>98%</sub>>98%) at the junction region and several dose statistics (D<sub>98%</sub>, D<sub>mean</sub>, and D<sub>2%</sub>) were compared between automatic and manual plans. The Modulation Complexity Score (MCS) was used to assess plan complexity.</p> <p><strong>Results</strong>: The automatic procedure required 60-90 minutes, depending on the case. All automatic plans achieved clinically acceptable dosimetric results (CTV_J-V<sub>98%</sub>>98%), with significant differences found at the junction region, where D<sub>mean </sub>and D<sub>2% </sub>increased on average by 2.4% (p<0.03) and 3.0% (p<0.02), respectively. Similar plan complexity was observed (median MCS=0.12). Since March 2022 the automatic procedure has been introduced in our clinic, reducing the TMI-TMLI simulation-to-delivery schedule by 2 days.</p> <p><strong>Conclusions</strong>: The developed procedure allowed to streamline the treatment planning of TMI-TMLI, increasing efficiency and standardization, preventing human errors, while maintaining the dosimetric plan quality and complexity of manual plans. Automated strategies can simplify the future adoption and clinical implementation of TMI-TMLI treatments in new centers.</p> <p> </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.